Technology Appraisal Committee Meeting (Committee B)

**Avonmouth House**

**Avonmouth Street**

**London**

**SE1 6NX**

# Minutes: Confirmed

## Date and Time: Thursday 12 March 2020, from 10am to 4pm

### Present:

1. Professor Amanda Adler (Chair) Present for all notes
2. Dr Sanjeev Patel (Vice-Chair) Present for all notes
3. Dr Laura Bojke Present for all notes
4. Professor John Cairns Present for notes 1 to 18
5. Mr Mark Chapman Present for all notes
6. Dr Susan Faulds Present for all notes
7. Dr Mark Glover Present for all notes
8. Mr Gareth Hooper Present for all notes
9. Dr Megan John Present for all notes
10. Dr Sanjay Kinra Present for all notes
11. Dr Nicholas Latimer Present for all notes
12. Dr Rhiannon Owen Present for all notes
13. Ms Anna Pracz Present for all notes
14. Dr Stephen Smith Present for all notes
15. Professor Nicky Welton Present for all notes
16. Mr Peter Wheatley Price Present for all notes
17. Professor Sarah Wild Present for all notes
18. Dr Ed Wilson Present for all notes
19. Mr Tony Wootton Present for all notes

### In attendance:

* Helen Knight, Programme Director, NICE, Present for all notes
* Nicole Elliott, Associate Director, NICE, Present for all notes
* Melinda Goodall, Associate Director, NICE, Present foe notes 1 to 18
* Joanne Ekeledo, Project Manager, NICE, Present for all notes
* Jeremy Powell, Project Manager, NICE, Present for notes 1 to 7 and notes 19 to 30
* Hannah Nicholas, Technical Analyst, NICE, Present for notes 1 to 18
* Ross Dent, Technical Adviser, NICE, Present for notes 1 to 18
* Jessica Cronshaw, Technical Analyst, NICE, Present for notes 19 to 30
* Eleanor Donegan, Technical Adviser, NICE, Present for notes 19 to 30
* Dr Amy Grove, Warwick Evidence, Evidence Review Group, Present for notes 1 to 16
* Mr Peter Auguste, Warwick Evidence, Evidence Review Group, Present for notes 1 to 16
* Mr Mubarak Patel, Warwick Evidence, Evidence Review Group, Present for notes 1 to 16
* Sarah Davis, School of Health and Related Research, Evidence Review Group, Present for notes 19 to 27
* Dr Edith Poku, School of Health and Related Research, Evidence Review Group, Present for notes 19 to 27
* Dr John Stevens, School of Health and Related Research, Evidence Review Group, Present for notes 19 to 27
* Mrs Jacqueline Krarup, Patient Expert, Present for notes 7 to 16
* Miss Caroline Smith, Patient Expert, Present for notes 7 to 16
* Dr Matt Craner, Clinical Expert, Director MS trials Unit and Consultant Neurologist, University of Oxford, Present for notes 7 to 16
* Mrs Carmel Wilkinson, Clinical Expert, Multiple Sclerosis Clinical Nurse Specialist, Present for notes 7 to 16
* Mr Malcolm Qualie, NHS Commissioning expert, Pharmacy Lead, Specialised Commissioning, NHS England, Present for notes 7 to 16
* Ms Kymmene Dawson, Patient Expert, Present for notes 19 to 27
* Mrs Nicola Housam, Clinical Expert, Advanced Nurse Practitioner, Pilgrim Hospital, Present for notes 19 to 27
* Dr Lea Solman, Clinical Expert, Consultant in Paediatric Dermatology, Great Ormond Street Hospital, Present for notes 19 to 27

### Non-public attendees:

* Helen Barnett, Medical Editor, NICE, Present for all notes
* Edgar Masanga, RIA, NICE, Present for all notes
* Ross Dent, Technical Advisor, NICE, Present for all notes

## Notes

### Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of siponimod for treating secondary progressive multiple sclerosis [ID1304] and crisaborole for treating mild to moderate atopic dermatitis in people aged 2 years and older [ID1195].
2. The Chair welcomed Dr Rhiannon Owen and Ms Anna Pracz to their first meeting as a member of the Appraisal Committee.
3. The Chair informed the Committee that Professor John Cairns and Mr Gareth Hooper were both leaving the Committee and that this would be their last meeting. The Chair and the Committee thanked them for their work over the years.
4. The Chair informed the Committee of the non-public observers at this meeting: Helen Barnett and Edgar Masanga.
5. Apologies were received from Dr Veline L'Esperance, Professor Allyson Pollock, Mr Nigel Westwood and Dr Stuart Williams.

### Any other Business

1. The Committee were given an update on the progress of other appraisals discussed at previous meetings.

### Notes from the last meeting

1. The minutes of the Committee meeting held on 11 February 2020 were approved.

## Appraisal of siponimod for treating secondary progressive multiple sclerosis [ID1304]

### Part 1 – Open session

1. The Chair welcomed the invited experts: Mr Peter Auguste, Dr Matt Craner, Dr Amy Grove, Mrs Jacqueline Krarup, Mr Mubarak Patel, Mr Malcolm Qualie, Miss Caroline Smith and Mrs Carmel Wilkinson to the meeting and they introduced themselves to the Committee.
2. The Chair welcomed company representatives from Novartis to the meeting.
3. The Chair asked all Committee members to declare any relevant interests.  
   1. Dr Amanda Adler, Dr Sanjeev Patel, Dr Laura Bojke, Professor John Cairns, Mr Mark Chapman, Dr Susan Faulds, Dr Mark Glover, Mr Gareth Hooper, Dr Megan John, Dr Sanjay Kinra, Dr Nicholas Latimer, Dr Rhiannon Owen, Ms Anna Pracz, Dr Stephen Smith, Professor Nicky Welton, Mr Peter Wheatley-Price, Professor Sarah Wild, Dr Ed Wilson and Mr Tony Wootton all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non- specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of siponimod for treating secondary progressive multiple sclerosis [ID1304].
4. The Chair asked all NICE Staff to declare any relevant interests.
   1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of siponimod for treating secondary progressive multiple sclerosis [ID1304].
5. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.
   1. Mr Peter Auguste, Dr Amy Grove, Mr Mubarak Patel, Mr Malcolm Qualie and Miss Caroline Smith declared that they knew of no personal specific financial interest, personal non-specific financial interest, non- personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of siponimod for treating secondary progressive multiple sclerosis [ID1304].
   2. Dr Matt Craner declared a personal non-specific financial interest as he has undertaken speaker duties and has provided educational courses for the following pharmaceutical companies: Teva, Roche, Novartis, Biogen, and Merck.
      1. It was agreed that this declaration would not prevent Dr Craner from participating in this section of the meeting.
   3. Mrs Jacqueline Krarup declared a personal non-specific interest as she was invited by Novartis to give a presentation on her experience of multiple sclerosis.
      1. It was agreed that this declaration would not prevent Mrs Krarup from participating in this section of the meeting.
   4. Mrs Carmel Wilkinson declared a personal specific financial interest as she has worked with Novartis on a project regarding Siponimod and ‘Benefits treatment landscapes’.
      1. It was agreed that this declaration would not prevent Mrs Wilkinson from participating in this section of the meeting.
6. The Chair introduced the lead team, Dr Mark Glove, Mr Nigel Westwood and Dr Nicholas Latimer who gave presentations on the clinical effectiveness and cost effectiveness of siponimod for treating secondary progressive multiple sclerosis [ID1304].
7. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
8. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
9. The Chair then thanked the experts and company and Evidence Review Group representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

### Part 2 – Closed session

1. The Committee continued to discuss the clinical and cost effectiveness of siponimod for treating secondary progressive multiple sclerosis [ID1304].
   1. The committee decision was based on consensus.
2. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

## Appraisal of crisaborole for treating mild to moderate atopic dermatitis in people aged 2 years and older [ID1195]

### Part 1 – Open session

1. The Chair welcomed the invited experts: Ms Kymmene Dawson, Sarah Davis, Mrs Nicola Housam, Dr Edith Poku, Dr Lea Solman and Dr John Stevens to the meeting and they introduced themselves to the Committee.
2. The Chair welcomed company representatives from Pfizer to the meeting.
3. The Chair asked all Committee members to declare any relevant interests  
   1. Dr Amanda Adler, Dr Sanjeev Patel, Dr Laura Bojke, Mr Mark Chapman, Dr Susan Faulds, Dr Mark Glover, Mr Gareth Hooper, Dr Megan John, Dr Sanjay Kinra, Dr Nicholas Latimer, Dr Rhiannon Owen, Ms Anna Pracz, Dr Stephen Smith, Professor Nicky Welton, Mr Peter Wheatley-Price, Professor Sarah Wild, Dr Ed Wilson and Mr Tony Wootton all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of crisaborole for treating mild to moderate atopic dermatitis in people aged 2 years and older [ID1195].
4. The Chair asked all NICE Staff to declare any relevant interests.  
   1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of crisaborole for treating mild to moderate atopic dermatitis in people aged 2 years and older [ID1195].
5. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.
   1. Ms Kymmene Dawson, Sarah Davis, Mrs Nicola Housam, Dr Edith Poku, Dr Lea Solman and Dr John Stevens declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non- specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of crisaborole for treating mild to moderate atopic dermatitis in people aged 2 years and older [ID1195].
6. The Chair introduced the lead team, Dr Stephen Smith, Mr Tony Wootton and Dr Laura Bojke who gave presentations on the clinical effectiveness and cost effectiveness of crisaborole for treating mild to moderate atopic dermatitis in people aged 2 years and older [ID1195].
7. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
8. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
9. The Chair then thanked the experts and company and Evidence Review Group representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

### Part 2 – Closed session

1. The Committee continued to discuss the clinical and cost effectiveness of crisaborole for treating mild to moderate atopic dermatitis in people aged 2 years and older [ID1195].
   1. The committee decision was based on consensus.
2. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

## Date, time and venue of the next meeting

1. Wednesday 13 May 2020 at 10am. The meeting will be held by videoconference.